{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T20:26:52Z","timestamp":1697142412650},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11883-005-0044-y","type":"journal-article","created":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T07:06:43Z","timestamp":1179817603000},"page":"335-343","source":"Crossref","is-referenced-by-count":3,"title":["New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin"],"prefix":"10.1007","volume":"7","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"44_CR1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227\u2013239.","journal-title":"Circulation"},{"key":"44_CR2","unstructured":"Keppel KG, Pearcy JN, Wagener DK: Trends in Racial and Ethnic-Specific Rates for the Health Status Indicators: United States, 1990\u201398. 2002. Available at http:\/\/www.cdc.gov\/nchs\/data\/statnt\/statnt23.pdf. Accessed on April 6, 2005."},{"key":"44_CR3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149\u20131158.","journal-title":"Lancet"},{"key":"44_CR4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685\u2013696.","journal-title":"Lancet"},{"key":"44_CR5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711\u20131718.","journal-title":"JAMA"},{"key":"44_CR6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Waters D, Brown WV, et al.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999, 341:70\u201376.","journal-title":"N Engl J Med"},{"key":"44_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group: MRC\/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7\u201322.","journal-title":"Lancet"},{"key":"44_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.292.4.E1","volume":"292","author":"S Nissen","year":"2004","unstructured":"Nissen S: Aggressive lipid-lowering therapy and regression of coronary atheroma. JAMA 2004, 292:1\u20133.","journal-title":"JAMA"},{"key":"44_CR9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495\u20131504.","journal-title":"N Engl J Med"},{"key":"44_CR10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425\u20131435.","journal-title":"N Engl J Med"},{"key":"44_CR11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","volume":"357","author":"TJ Smilde","year":"2001","unstructured":"Smilde TJ, van Wissen S, Wollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577\u2013581.","journal-title":"Lancet"},{"key":"44_CR12","first-page":"1772","volume":"44","author":"MJ Koren","year":"2004","unstructured":"Koren MJ, Hunninghake DB: Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004, 44:1772\u20131779.","journal-title":"J Am Coll Cardiol"},{"key":"44_CR13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996, 335:1001\u20131009.","journal-title":"N Engl J Med"},{"key":"44_CR14","doi-asserted-by":"crossref","unstructured":"Sever PS, Dahlof B, Poulter NR, et al.: Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): early benefits on coronary heart disease risk reduction but stroke risk reduction occurs later. Am J Cardiol 2005, In press.","DOI":"10.1016\/j.amjcard.2005.06.025"},{"key":"44_CR15","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","volume":"106","author":"AJ Taylor","year":"2002","unstructured":"Taylor AJ, Kent SM, Flaherty PJ, et al.: ARBITER: ARterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002, 106:2055\u20132060.","journal-title":"Circulation"},{"key":"44_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00280-0","volume":"165","author":"S Wissen van","year":"2002","unstructured":"van Wissen S, Trip MD, Smilde TJ, et al.: Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002, 165:361\u2013366.","journal-title":"Atherosclerosis"},{"key":"44_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20\u201328.","journal-title":"N Engl J Med"},{"key":"44_CR18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0002-9149(02)02306-8","volume":"89","author":"S Kinlay","year":"2002","unstructured":"Kinlay S, Timms T, Clark M, et al.: Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002, 89:1205\u20131207.","journal-title":"Am J Cardiol"},{"key":"44_CR19","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","volume":"108","author":"S Kinlay","year":"2003","unstructured":"Kinlay S, Schwartz GG, Olsson AG, et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560\u20131566.","journal-title":"Circulation"},{"key":"44_CR20","unstructured":"Baycol Recall Information: Bayer Recalls Baycol Due to Rhabdomylosis. 2001. Available at www.baycol-rhabdomyolysis.com\/baycol_recall\/. Accessed April 2, 2005."},{"key":"44_CR21","doi-asserted-by":"crossref","first-page":"3K","DOI":"10.1016\/S0002-9149(03)00768-9","volume":"92","author":"C Ballantyne","year":"2003","unstructured":"Ballantyne C: Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 2003, 92:3K-9K.","journal-title":"Am J Cardiol"},{"key":"44_CR22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14740338.1.3.269","volume":"1","author":"M Moghadasian","year":"2002","unstructured":"Moghadasian M: A safety look at currently available statins. Exp Opin Drug Safety 2002, 1:269\u2013274.","journal-title":"Exp Opin Drug Safety"},{"key":"44_CR23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","volume":"92","author":"CB Newman","year":"2003","unstructured":"Newman CB, Palmer G, Silbershatz HS, Zarek M: Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003, 92:670\u2013676.","journal-title":"Am J Cardiol"},{"key":"44_CR24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0002-9149(01)02209-3","volume":"89","author":"R Benghozi","year":"2002","unstructured":"Benghozi R, Bortolini M, Jia Y, et al.: Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002, 89:231\u2013233.","journal-title":"Am J Cardiol"},{"key":"44_CR25","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjcard.2004.06.049","volume":"94","author":"J Shepherd","year":"2004","unstructured":"Shepherd J, Hunninghake DB, Stein EA, et al.: Safety of rosuvastatin. Am J Cardiol 2004, 94:882\u2013888.","journal-title":"Am J Cardiol"},{"key":"44_CR26","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","volume":"105","author":"MA Pfeffer","year":"2002","unstructured":"Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation 2002, 105:2341\u20132346.","journal-title":"Circulation"},{"key":"44_CR27","doi-asserted-by":"crossref","unstructured":"Newman C, Tsai J, Szarek M, et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2005, Submitted.","DOI":"10.1016\/j.amjcard.2005.07.108"},{"key":"44_CR28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681\u20131690.","journal-title":"JAMA"},{"key":"44_CR29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","volume":"43","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 43:567\u2013571.","journal-title":"J Am Coll Cardiol"},{"key":"44_CR30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-133-7-200010030-00015","volume":"133","author":"TA Jacobson","year":"2000","unstructured":"Jacobson TA: The lower the better in hypercholesterolemia therapy: a reliable clinical guideline? Ann Intern Med 2000, 133:549\u2013554.","journal-title":"Ann Intern Med"},{"key":"44_CR31","first-page":"29","volume":"12","author":"P Lindgren","year":"2005","unstructured":"Lindgren P, Buxton M, Kahan T, et al.: Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 2005, 12:29\u201336.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"44_CR32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.amjcard.2003.06.009","volume":"92","author":"GG Schwartz","year":"2003","unstructured":"Schwartz GG, Ganz P, Waters D, Arikian S: Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol 2003, 92:1109\u20131112.","journal-title":"Am J Cardiol"},{"key":"44_CR33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-132-10-200005160-00002","volume":"132","author":"LA Prosser","year":"2000","unstructured":"Prosser LA, Stinnett AA, Goldman PA, et al.: Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000, 132:769\u2013779.","journal-title":"Ann Intern Med"},{"key":"44_CR34","unstructured":"Koren MJ, Schwartz SJ, Drummond MF: Cost-effectiveness of intensive atorvastatin therapy in patients following acute coronary syndromes. J Am Coll Cardiol 2005, 45:347A."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-005-0044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-005-0044-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-005-0044-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:35:28Z","timestamp":1559417728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-005-0044-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s11883-005-0044-y","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}